Therapy News and Research

RSS

Zytiga is commonly prescribed for second-line treatment of mCRPC patients

Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).

18 Nov 2014

Study identifies new gene for progressive form of epilepsy

A study led by researchers at University of Helsinki, Finland and Universities of Melbourne and South Australia has identified a new gene for a progressive form of epilepsy. The findings of this international collaborative effort have been published today, 17 November 2014, in Nature Genetics.

18 Nov 2014

New study investigates patient perspectives on deactivation of ICDs at the end of life

Most patients with implantable cardioverter defibrillators (ICDs)--small devices placed in a person's chest to help treat irregular heartbeats with electrical pulses, or shocks--haven't thought about device deactivation if they were to develop a serious illness from which they were not expected to recover.

18 Nov 2014

TapImmune signs new collaborative research agreement with VGTI Florida

TapImmune, Inc., is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida, a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.

18 Nov 2014

New oral medication shows promise in treating fibromyalgia

A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.

18 Nov 2014

Pros and cons of medical marijuana to be discussed at Queensland Epilepsy Symposium

The pros and cons of medical marijuana is a discussion focus at the fifth annual Queensland Epilepsy Symposium, Epilepsy – On the Horizon.

18 Nov 2014

VEGF-B can regenerate damaged peripheral nerves without causing growth of new blood vessels

Researchers at the University of Illinois at Chicago College of Medicine have found that a growth factor can regenerate damaged peripheral nerves without causing the growth of new blood vessels -- making it a unique candidate to treat nerve damage in areas of the body where the proliferation of blood vessels would be a drawback.

18 Nov 2014

Adding ezetimibe to statin therapy reduces cardiovascular events

More than a decade ago, researchers from Brigham and Women's Hospital demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events.

18 Nov 2014

Drug combination shows promise in patients with newly diagnosed multiple myeloma

The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology.

18 Nov 2014

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today presented detailed results from HARMONIZE (ZS004) at the late-breaking Clinical Science Special Reports Session of the American Heart Association Scientific Sessions.

18 Nov 2014

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA.

18 Nov 2014

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone.

17 Nov 2014

Beckman Coulter Life Sciences contributes its flow cytometry expertise to support the ONE Study

Beckman Coulter Life Sciences participates in the ONE Study, international collaboration of scientists across Europe and the USA.

From Beckman Coulter Life Sciences - Flow Cytometry 17 Nov 2014

Three Johns Hopkins hospitals recognized as Top Performer on Key Quality Measures

Three Johns Hopkins Medicine hospitals are recipients of The Joint Commission’s 2013 Top Performer on Key Quality Measures award. The Top Performer program recognizes hospitals for improving performance on evidence-based interventions that increase the chances of healthy outcomes for patients with certain conditions, including heart attack, heart failure, pneumonia, surgical care, children’s asthma, stroke, venous thromboembolism (VTE) and perinatal care, as well as for inpatient psychiatric services and immunizations.

17 Nov 2014

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

17 Nov 2014

Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Prostate cancer patients carrying inherited mutations in the BRCA genes respond less well to conventional treatment, including surgery and/or radiotherapy - and they also have a lower survival rate than those who are non-carriers of these genetic mutations. Data from the study, which has been published in the journal European Urology, points to the need for new clinical trials aimed at targeting these mutations in order to tailor treatment for these patients.

17 Nov 2014

Discovery opens up new routes to strengthen anti-smoking efforts to control TB

TB is an infectious disease that kills 1.5 million people each year, and smoking is the biggest driver of the global TB epidemic. Medical scientists at Trinity College Dublin and St James's Hospital in Ireland have unlocked the mechanism underlying the connection between smoking and Tuberculosis (TB).

17 Nov 2014

Therapy News and Research

Zytiga is commonly prescribed for second-line treatment of mCRPC patients

Study identifies new gene for progressive form of epilepsy

New study investigates patient perspectives on deactivation of ICDs at the end of life

TapImmune signs new collaborative research agreement with VGTI Florida

New oral medication shows promise in treating fibromyalgia

Pros and cons of medical marijuana to be discussed at Queensland Epilepsy Symposium

VEGF-B can regenerate damaged peripheral nerves without causing growth of new blood vessels

Adding ezetimibe to statin therapy reduces cardiovascular events

Drug combination shows promise in patients with newly diagnosed multiple myeloma

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

Beckman Coulter Life Sciences contributes its flow cytometry expertise to support the ONE Study

Three Johns Hopkins hospitals recognized as Top Performer on Key Quality Measures

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Discovery opens up new routes to strengthen anti-smoking efforts to control TB

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Sarcomatoid differentiation levels predict poor RCC survival

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News